ILC Therapeutics Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $3.18M

  • Investors
  • 6

ILC Therapeutics General Information

Description

Developer of novel peptide therapeutics intended to find a cure against COVID-19, ARDS, Oncology, Psoriasis and Atopic Dermatitis. The company builds interferon medicines called hybrid interferons that take features of natural interferon subtypes and combine them into one new hybrid interferon molecule that is designed to deliver enhanced efficacy and improved safety over a range of high-value therapeutic areas, enabling healthcare professionals to improve patient outcomes and find a cure against diseases.

Contact Information

Formerly Known As
Alfacyte
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 100 West George Street
  • Glasgow G2 1PP
  • Scotland, United Kingdom
+44 0141
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Corporate Office
  • 100 West George Street
  • Glasgow G2 1PP
  • Scotland, United Kingdom
+44 0141

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ILC Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series A) 28-Jun-2024 $3.18M Completed Generating Revenue
6. Later Stage VC 06-Sep-2021 Completed Generating Revenue
5. Later Stage VC 27-Nov-2020 Completed Generating Revenue
4. Accelerator/Incubator 15-Nov-2019 Completed Generating Revenue
3. Later Stage VC 09-Jul-2018 Completed Generating Revenue
2. Later Stage VC 14-Dec-2017 $567K $957K Completed Generating Revenue
1. Seed Round 30-Jul-2015 $390K $390K Completed Startup
To view ILC Therapeutics’s complete valuation and funding history, request access »

ILC Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
A Ordinary
A Ordinary
A Ordinary
A Ordinary
A Ordinary
A Ordinary
A Ordinary
A Ordinary
A Ordinary 27,213 $1.271303 $11.21 $11.21 1x $11.21 3.76%
A Ordinary 5,555 $1.271303 $2.29 $2.29 1x $2.29 0.77%
To view ILC Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

ILC Therapeutics Patents

ILC Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202314249-D0 Compositions and method for treating disease Inactive 18-Sep-2023
ES-2981369-T3 Composition and methods relating to the treatment of diseases Active 17-Feb-2021
JP-2024507313-A Compositions and methods related to the treatment of diseases Pending 17-Feb-2021
AU-2022223363-A1 Compositions and methods relating to the treatment of diseases Inactive 17-Feb-2021
CA-3190362-A1 Compositions and methods relating to the treatment of diseases Pending 17-Feb-2021 A61K38/212
To view ILC Therapeutics’s complete patent history, request access »

ILC Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ILC Therapeutics Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
ILCT management Venture Capital Minority
Angel (individual) Minority
Medical Incubator Japan Venture Capital Minority
Pioneer Group Venture Capital Minority
Eos Advisory Venture Capital Minority
You’re viewing 5 of 6 investors. Get the full list »

ILC Therapeutics FAQs

  • When was ILC Therapeutics founded?

    ILC Therapeutics was founded in 2012.

  • Where is ILC Therapeutics headquartered?

    ILC Therapeutics is headquartered in Glasgow, United Kingdom.

  • What is the size of ILC Therapeutics?

    ILC Therapeutics has 3 total employees.

  • What industry is ILC Therapeutics in?

    ILC Therapeutics’s primary industry is Drug Discovery.

  • Is ILC Therapeutics a private or public company?

    ILC Therapeutics is a Private company.

  • What is the current valuation of ILC Therapeutics?

    The current valuation of ILC Therapeutics is .

  • What is ILC Therapeutics’s current revenue?

    The current revenue for ILC Therapeutics is .

  • How much funding has ILC Therapeutics raised over time?

    ILC Therapeutics has raised $13.1M.

  • Who are ILC Therapeutics’s investors?

    ILCT management, , Medical Incubator Japan, Pioneer Group, and Eos Advisory are 5 of 6 investors who have invested in ILC Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process